Highlights Immunome, Inc.

Equities

IMNM

US45257U1088

Real-time Estimate Cboe BZX Other stock markets 10:04:23 2024-05-14 EDT			5-day change	1st Jan Change
15.29 ^USD	-2.05%		-1.66%	+40.89%

12:00am	Certain Common Stock of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI
12:00am	Certain Warrants of Immunome, Inc. are subject to a Lock-Up Agreement Ending on 14-MAY-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Immunome, Inc. completed the acquisition of Assets from Ayala Pharmaceuticals, Inc..	03-24	CI
Immunome to Acquire Potential Desmoid Tumor Treatment From Ayala Pharmaceuticals; Shares Climb	02-06	MT
Immunome, Inc. entered into a definitive asset purchase agreement to acquire Assets from Ayala Pharmaceuticals, Inc. for $94.2 million.	02-05	CI
Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate	01-08	CI
Immunome Signs Asset Purchase Agreement for Acquisition of Antibody-Related Assets From Atreca	12-26	MT
Immunome, Inc. entered into an agreement to acquire Substantially all Assets of Atreca, Inc. for $12.5 million.	12-25	CI
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Immunome, Inc. completed the acquisition of MorphImmune, Inc. from Research Bridge Partners, Investment Arm and others.	23-10-01	CI
Immunome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Immunome, Morphimmune Agree to Merge in All-Stock Deal	23-06-29	MT
Immunome, Inc. entered into an agreement to acquire MorphImmune, Inc.	23-06-28	CI
Immunome, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-05	CI
Immunome, Inc. Enter into A Collaboration and Option Agreement with AbbVie Global Enterprises Ltd	23-01-06	CI
Immunome, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Immunome Says 'Encouraged' by Preclinical Data in Cancer Trial	22-11-09	MT
Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s 37th Annual Meeting	22-11-07	CI
Immunome Announces Publication in Clinical & Translational Immunology Highlighting B Cell Repertoires in Patients with Breast Cancer	22-08-23	CI
Immunome, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-05	CI
Immunome, Inc.’S Covid-19 Cocktail Retains Neutralizing Activity Against the Most Prevalent Omicron Subvariants in the Us, Ba.4/5 and Ba.2.12.1	22-07-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Immunome, Inc.

Equities

IMNM

US45257U1088

Highlights

Filters